Abstract
Gastrointestinal stromal tumour is the most frequent non-epithelial tumour of the gastrointestinal tract. In recent years, there has been a very rapid progress in the options of its systemic treatment.
The efficacy of biological agents in palliative indication has been the reason for their introduction even in the adjuvant setting. Imatinib is the mainstay of the first palliative line as well as of the adjuvant indication in high-risk resected GISTs.
Following its failure in the initial dose, its escalation is recommended and only subsequently treatment with other biological agents, such as sunitinib or regorafenib. There is a whole range of agents that were or currently are investigated in clinical trials.